Get the Stockscreener App
1.58
2.47%
-0.04
After Hours:
1.60
0.02
+1.27%
In 8 Bio Inc stock is traded at $1.58, with a volume of 74,709.
It is down -2.47% in the last 24 hours and up +12.06% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.62
Open:
$1.68
24h Volume:
74,709
Relative Volume:
1.27
Market Cap:
$15.56M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.5943
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
+4.64%
1M Performance:
+12.06%
6M Performance:
-4.82%
1Y Performance:
-67.85%
1-Day Range:
$1.50
$1.69
1-Week Range:
$1.44
$1.69
52-Week Range:
$1.17
$5.61
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.58 | 15.95M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences - GlobeNewswire Inc.
BLTE SEC FilingsBelite Bio, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
Valion Bio (Nasdaq: VBIO) hires Melinda Lackey as General Counsel - Stock Titan
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
Cabaletta Bio (NASDAQ: CABA) prices $150M equity raise to fund rese-cel - Stock Titan
Cabaletta Bio (NASDAQ: CABA) to share new rese-cel RESET-PV data at ASGCT 2026 - Stock Titan
Leadership shake-up at TELA Bio (NASDAQ: TELA) as new chair named - Stock Titan
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - The Manila Times
[ARS] Boundless Bio, Inc. SEC Filing - Stock Titan
Adicet Bio (NASDAQ: ACET) issues 250,000-share pre-funded warrant in exchange deal - Stock Titan
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
BIO-key International, Inc. Files 8-K Report on Security Holder Vote Results – April 2026 - Minichart
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
[ARS] Instil Bio, Inc. SEC Filing - Stock Titan
BIO-key (NASDAQ: BKYI) wins approval for flexible reverse stock split - Stock Titan
[ARS] Gossamer Bio, Inc. SEC Filing - Stock Titan
Q32 Bio (NASDAQ: QTTB) adds $75M ATM common stock capacity - Stock Titan
Valion Bio (Nasdaq: TIVC) pivots to late-stage biopharma with Entolimod and CDMO - Stock Titan
Tevogen Bio (NASDAQ: TVGN) warned on Nasdaq $50M, $15M value tests - Stock Titan
Nasdaq warns BIO-key (NASDAQ: BKYI) after delayed 2025 Form 10-K - Stock Titan
CLYM (Climb Bio Inc.) rises 3.85 percent even as fourth quarter 2025 per share earnings miss analyst estimates.Sector Outperform - Xã Châu Thành
Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update - Stock Titan
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Rese-cel data expands across autoimmune diseases at Cabaletta Bio (CABA) - Stock Titan
Nasdaq warns Mustang Bio (MBIO) on sub-$1 share price and listing risk - Stock Titan
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Yahoo Finance
CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred - Stock Titan
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks - Yahoo Finance
Bio Green Med Solution, Inc. Files Form 8-K with SEC – Company Details, Nasdaq Listing, and Contact Information (April 2026) - Minichart
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Insider Monkey
Gossamer Bio, Inc. 8-K SEC Filing April 2026 – NASDAQ Listing, Company Details, and Compliance Information - Minichart
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Gossamer Bio Received Notice of Noncompliance - TradingView
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq warns Gossamer Bio (NASDAQ: GOSS) over sub-$1 share price - Stock Titan
ImmunityBio (NASDAQ: IBRX) Q1 revenue jumps 168% to $44.2M - Stock Titan
Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS - Morningstar
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - ChartMill
[ARS] Passage BIO, Inc. SEC Filing - Stock Titan
8 Most Oversold Penny Stocks to Buy Right Now - Insider Monkey
Adaptin Bio shares approved for OTCQB quotation under ticker APTN; trading to begin in 6-8 weeks - TradingView
Adaptin Bio (APTN) wins OTCQB quotation and advances APTN-101 program - Stock Titan
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):